Cardiac Biomarkers Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Cardiac biomarkers play a critical role in modern cardiology by enabling rapid detection of cardiac events and monitoring of heart conditions. The global market spans a range of tests and platforms, including troponin assays, brain natriuretic peptide (BNP) measurements, and tests for acute coronary syndrome and myocardial infarction. Market value in 2025 ranges from $20.4 billion to $25.2 billion across various industry estimates, with most projections extending to 2030 or beyond.

• •Market encompasses in-vitro diagnostic tests and instruments for cardiac-specific proteins and enzymes
• •Troponin and BNP represent the most widely used biomarker categories in clinical practice
• •Growth projections vary by source but consistently show strong expansion over the next decade

The increasing global burden of cardiovascular disease remains the primary driver of market expansion. Rising prevalence of heart attacks, heart failure, and related conditions, combined with aging demographics in developed and developing nations, is expanding the patient population requiring biomarker testing. Additionally, advances in diagnostic technology, including point-of-care testing and high-sensitivity assays, are improving accuracy, speed, and accessibility of cardiac diagnostics.

• •Growing demand for routine screening and early diagnosis of cardiovascular conditions
• •Technological improvements in high-sensitivity troponin and point-of-care devices
• •Increasing healthcare expenditure and awareness of cardiac disease prevention

The market is segmented by biomarker type, application, and testing location. Troponin tests dominate the market, followed by BNP and CK-MB assays. Applications include acute coronary syndrome, heart failure, and myocardial infarction diagnosis. Testing is divided between laboratory-based and point-of-care settings, with both segments seeing growth. Geographically, North America leads due to advanced healthcare infrastructure, while Asia-Pacific is expected to grow fastest driven by improving access and rising disease prevalence.

• •Troponin and acute coronary syndrome segments account for the largest market shares
• •Point-of-care testing is gaining market share due to faster turnaround and workflow efficiency
• •Asia-Pacific and emerging markets represent the fastest-growing regional segments

What are the recent trends and outlook?

The market is moving toward more rapid, decentralized testing through point-of-care devices, reducing the time between symptom onset and diagnosis. There is also growing interest in multiplex assays that measure multiple biomarkers simultaneously to improve diagnostic accuracy. Integration with electronic health records and artificial intelligence for result interpretation represents an emerging opportunity. The market is expected to reach between $49 billion and $98 billion by the early 2030s, depending on the source and forecast period, reflecting sustained investment in cardiac diagnostics.

• •Point-of-care and near-patient testing adoption continues to accelerate
• •Development of high-sensitivity and next-generation biomarker assays underway
• •Digital integration and AI-assisted interpretation expected to shape future product development